Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin

Journal of Pharmaceutical Analysis(2021)10.1016/j.jpha.2021.02.004Source: DataRank Database

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin is a research paper published in Journal of Pharmaceutical Analysis (2021). On theSindex it has a DataRank of 0. It has been cited 32 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access32 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 3.26)OA: goldTopics (20)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Shihui Yu ORCID,Guihong Chai ORCID,Junting Liu ORCID,Qi Zhou ORCID,Huiya Yuan ORCID

Live enrichment

PubMed:35028178 PMC:PMC8740159 OpenAlex:https://openalex.org/W3134414649

National Institute of Allergy and Infectious Diseases

Grant: R01AI132681

National Institute of Allergy and Infectious Diseases

Grant: R01AI146160

National Institutes of Health

FWCI

3.26

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.jpha.2021.02.004

publisherhttps://doi.org/10.1016/j.jpha.2021.02.004

publisherhttps://api.elsevier.com/content/article/PII:S2095177921000198?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2095177921000198?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35028178

Fields of Study

Cystic Fibrosis Research AdvancesBiosensors and Analytical DetectionAntibiotic Resistance in Bacteria

Keywords

IvacaftorChemistryCiprofloxacinCystic fibrosisColistinPharmacologyTherapeutic drug monitoringChromatographyDrugAntibioticsInternal medicineCystic fibrosis transmembrane conductance regulatorBiochemistryMedicinePlasmaHplc-ms/msLung Epithelial Cells

Sustainable Development Goals

SDG 0: Good health and well-being